InterK Peptide Therapeutics functions largely as a virtual company and located in Sydney, Australia.
All research is conducted on a fee for service basis and the Company owns all intellectual property associated with its research program and technologies.
The company’s R&D program is supported by Contract Research Organisations located within Australia and overseas.
All three assets share the ability to inhibit cancer growth in vivo in murine models but also differ significantly in their respective immunomodulating effects on expression of cytokines, cytokine receptors and regulation of signalling pathways within T cells, natural killer cells and antigen-presenting cells.
The three different compounds share a common core amino acid sequence which was developed by rational drug design arising from discovery of a receptor-MAP kinase interaction.